These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33930412)

  • 1. Tissue-resident macrophages mediate neutrophil recruitment and kidney injury in shiga toxin-induced hemolytic uremic syndrome.
    Lill JK; Thiebes S; Pohl JM; Bottek J; Subramaniam N; Christ R; Soun C; Gueler F; Zwanziger D; Hoffmann F; von Eggeling F; Bracht T; Sitek B; Hickey MJ; Hofnagel O; Engel DR
    Kidney Int; 2021 Aug; 100(2):349-363. PubMed ID: 33930412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.
    Proulx F; Seidman EG; Karpman D
    Pediatr Res; 2001 Aug; 50(2):163-71. PubMed ID: 11477199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR2-dependent Gr1
    Pohl JM; Volke JK; Thiebes S; Brenzel A; Fuchs K; Beziere N; Ehrlichmann W; Pichler BJ; Squire A; Gueler F; Engel DR
    Eur J Immunol; 2018 Jun; 48(6):990-1000. PubMed ID: 29446073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation.
    Roche JK; Keepers TR; Gross LK; Seaner RM; Obrig TG
    Am J Pathol; 2007 Feb; 170(2):526-37. PubMed ID: 17255321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent roles of haptoglobin and hemopexin deficiency for disease progression of Shiga-toxin-induced hemolytic-uremic syndrome in mice.
    Pirschel W; Mestekemper AN; Wissuwa B; Krieg N; Kröller S; Daniel C; Gunzer F; Tolosano E; Bauer M; Amann K; Heinemann SH; Coldewey SM
    Kidney Int; 2022 Jun; 101(6):1171-1185. PubMed ID: 35031328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome.
    Ramos MV; Mejias MP; Sabbione F; Fernandez-Brando RJ; Santiago AP; Amaral MM; Exeni R; Trevani AS; Palermo MS
    J Innate Immun; 2016; 8(4):400-11. PubMed ID: 27230920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hemolytic uremic syndrome caused by enterohaemorrhagic Escherichia coli].
    Ibarra C; Goldstein J; Silberstein C; Zotta E; Belardo M; Repetto HA
    Arch Argent Pediatr; 2008 Oct; 106(5):435-42. PubMed ID: 19030644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome.
    Alconcher LF; Coccia PA; Suarez ADC; Monteverde ML; Perez Y Gutiérrez MG; Carlopio PM; Missoni ML; Balestracci A; Principi I; Ramírez FB; Estrella P; Micelli S; Leroy DC; Quijada NE; Seminara C; Giordano MI; Hidalgo Solís SB; Saurit M; Caminitti A; Arias A; Rivas M; Risso P; Liern M
    Pediatr Nephrol; 2018 Oct; 33(10):1791-1798. PubMed ID: 29961127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volume Resuscitation and Progression to Organ Failure in Shiga Toxin-Producing
    Volk CG; Cusmano PM; Bower RJ; Sanders T; Maves RC
    Crit Care Explor; 2021 May; 3(5):e0423. PubMed ID: 34036274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome.
    Braune SA; Wichmann D; von Heinz MC; Nierhaus A; Becker H; Meyer TN; Meyer GP; Müller-Schulz M; Fricke J; de Weerth A; Hoepker WW; Fiehler J; Magnus T; Gerloff C; Panzer U; Stahl RA; Wegscheider K; Kluge S
    Crit Care Med; 2013 Jul; 41(7):1702-10. PubMed ID: 23660733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome.
    Brigotti M; Tazzari PL; Ravanelli E; Carnicelli D; Rocchi L; Arfilli V; Scavia G; Minelli F; Ricci F; Pagliaro P; Ferretti AV; Pecoraro C; Paglialonga F; Edefonti A; Procaccino MA; Tozzi AE; Caprioli A
    Pediatr Infect Dis J; 2011 Jun; 30(6):486-90. PubMed ID: 21164386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.
    Karpman D; Tati R
    Kidney Int; 2016 Oct; 90(4):726-9. PubMed ID: 27633864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microvesicle Involvement in Shiga Toxin-Associated Infection.
    Villysson A; Tontanahal A; Karpman D
    Toxins (Basel); 2017 Nov; 9(11):. PubMed ID: 29156596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
    Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
    Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature.
    Ko H; Maymani H; Rojas-Hernandez C
    J Med Case Rep; 2016 Jun; 10():175. PubMed ID: 27301547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemolytic uremic syndrome with simultaneous Shiga toxin producing Escherichia coli and complement abnormalities.
    McCoy N; Weaver DJ
    BMC Pediatr; 2014 Nov; 14():278. PubMed ID: 25373393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany.
    Frank C; Werber D; Cramer JP; Askar M; Faber M; an der Heiden M; Bernard H; Fruth A; Prager R; Spode A; Wadl M; Zoufaly A; Jordan S; Kemper MJ; Follin P; Müller L; King LA; Rosner B; Buchholz U; Stark K; Krause G;
    N Engl J Med; 2011 Nov; 365(19):1771-80. PubMed ID: 21696328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human monocytes stimulated by Shiga toxin 1a via globotriaosylceramide release proinflammatory molecules associated with hemolytic uremic syndrome.
    Brigotti M; Carnicelli D; Arfilli V; Porcellini E; Galassi E; Valerii MC; Spisni E
    Int J Med Microbiol; 2018 Oct; 308(7):940-946. PubMed ID: 29983334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome.
    Kröller S; Wissuwa B; Dennhardt S; Krieg N; Thiemermann C; Daniel C; Amann K; Gunzer F; Coldewey SM
    Front Immunol; 2023; 14():1105181. PubMed ID: 36911665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic functions and diagnostic utility of cytokines/chemokines in EHEC-HUS.
    Shimizu M
    Pediatr Int; 2020 Mar; 62(3):308-315. PubMed ID: 31742829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.